Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia
Aims and Method. To evaluate the practical utility of off-licence prescribing and clinical outcomes of treatment with atypical antipsychotic Melperone. Method: Prospective data collection on patient’s clinical characteristics and outcomes. Results. 17 patients with a diagnosis of refractory schizoph...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/512047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564639372673024 |
|---|---|
| author | Frank Röhricht Seema Gadhia Rinku Alam Melissa Willis |
| author_facet | Frank Röhricht Seema Gadhia Rinku Alam Melissa Willis |
| author_sort | Frank Röhricht |
| collection | DOAJ |
| description | Aims and Method. To evaluate the practical utility of off-licence prescribing and clinical outcomes of treatment with atypical antipsychotic Melperone. Method: Prospective data collection on patient’s clinical characteristics and outcomes. Results. 17 patients with a diagnosis of refractory schizophrenia were identified as suitable for off-license prescribing of Melperone and commenced treatment (13 were previously treated with Clozapine). Seven of those currently remain on Melperone (41%), and for six patents, the BPRS symptom scores reduced significantly over time (24–61%) additionally patients displayed improvements of their quality of life. Six patients were discontinued due to noncompliance and/or side effects. Melperone was ineffective in the other four patients. Clinical Implications. The example of a small group of patients responding well to a comparably safe and inexpensive atypical antipsychotic with favourable side effect profile should encourage clinicians to use this tool as third-line treatment and to conduct more systematic clinical research. |
| format | Article |
| id | doaj-art-d80694b515ff4ce392c657b680f983c5 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-d80694b515ff4ce392c657b680f983c52025-02-03T01:10:38ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/512047512047Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory SchizophreniaFrank Röhricht0Seema Gadhia1Rinku Alam2Melissa Willis3Newham Centre for Mental Health, East London NHS Foundation Trust and University of Essex, London E13 8SP, UKBuckinghamshire NHS Primary Care Trust, Community Pharmacy, Aylesbury HP19 8ET, UKNorth East London NHS Foundation Trust, General Adult Psychiatry, Ilford, Essex IG3 8XJ, UKKent and Medway NHS and Social Care Partnership Trust, Kent ME19 4AX, UKAims and Method. To evaluate the practical utility of off-licence prescribing and clinical outcomes of treatment with atypical antipsychotic Melperone. Method: Prospective data collection on patient’s clinical characteristics and outcomes. Results. 17 patients with a diagnosis of refractory schizophrenia were identified as suitable for off-license prescribing of Melperone and commenced treatment (13 were previously treated with Clozapine). Seven of those currently remain on Melperone (41%), and for six patents, the BPRS symptom scores reduced significantly over time (24–61%) additionally patients displayed improvements of their quality of life. Six patients were discontinued due to noncompliance and/or side effects. Melperone was ineffective in the other four patients. Clinical Implications. The example of a small group of patients responding well to a comparably safe and inexpensive atypical antipsychotic with favourable side effect profile should encourage clinicians to use this tool as third-line treatment and to conduct more systematic clinical research.http://dx.doi.org/10.1100/2012/512047 |
| spellingShingle | Frank Röhricht Seema Gadhia Rinku Alam Melissa Willis Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia The Scientific World Journal |
| title | Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia |
| title_full | Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia |
| title_fullStr | Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia |
| title_full_unstemmed | Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia |
| title_short | Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia |
| title_sort | auditing clinical outcomes after introducing off licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia |
| url | http://dx.doi.org/10.1100/2012/512047 |
| work_keys_str_mv | AT frankrohricht auditingclinicaloutcomesafterintroducingofflicenceprescribingofatypicalantipsychoticmelperoneforpatientswithtreatmentrefractoryschizophrenia AT seemagadhia auditingclinicaloutcomesafterintroducingofflicenceprescribingofatypicalantipsychoticmelperoneforpatientswithtreatmentrefractoryschizophrenia AT rinkualam auditingclinicaloutcomesafterintroducingofflicenceprescribingofatypicalantipsychoticmelperoneforpatientswithtreatmentrefractoryschizophrenia AT melissawillis auditingclinicaloutcomesafterintroducingofflicenceprescribingofatypicalantipsychoticmelperoneforpatientswithtreatmentrefractoryschizophrenia |